NeurAxis Neurostimulation
NeurAxis Neurostimulation
NeurAxis Neurostimulation

Neuromodulation therapies for chronic and debilitating conditions

Targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interactions (DGBIs).

Neuromodulation therapies for chronic and debilitating conditions

Targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interactions (DGBIs).

Gut–brain axis

Reimagining the future of patient care

The gut–brain axis is one of the most powerful relationships in our body.

Functional abdominal pain associated with irritable bowel syndrome (IBS) is believed to involve abnormal processing between the gut and the brain. Specifically, studies in individuals with IBS have demonstrated abnormal activation of an area in the brain called the amygdala, which processes pain.

Through innovation and research, NeurAxis is reimagining the future of patient care so that all children, and the adults they grow up to be, can experience the lifelong benefits of being free from chronic pain. We are continually evolving to also address the unmet health care needs of adults suffering from gastrointestinal issues.

PENFS (Percutaneous Electrical Nerve Field Stimulation)

Introducing IB-Stim

IB-Stim is a first-to-market, FDA cleared, drug-free and non-surgical device worn behind the ear. IB-Stim is indicated for functional abdominal pain associated with IBS in adolescents (ages 8-21) without serious side effects or complications.

NEURAXIS MISSION

Improving lives and minimizing suffering

Our Mission at NeurAxis is to provide solutions that create value and provide better and safer patient outcomes. We believe in improving lives and minimizing suffering; particularly in the pediatric population.

Latest News

Neuromodulation Therapies For Chronic And Debilitating Conditions In Children

Neuromodulation Therapies For Chronic And Debilitating Conditions In Children

Targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interactions (DGBIs).